Skip to main content
Infection and Immunity logoLink to Infection and Immunity
. 1996 Aug;64(8):3081–3087. doi: 10.1128/iai.64.8.3081-3087.1996

Escherichia coli hemolysin mutants with altered target cell specificity.

S Pellett 1, R A Welch 1
PMCID: PMC174191  PMID: 8757837

Abstract

In order to understand the functional significance of HlyC-dependent acylation of the Escherichia coli hemolysin structural protein (HlyA), random as well as site-directed substitutions at the known regions of modification, i.e., those at lysine residues at amino acid positions 563 and 689 (HlyAK563 and HlyAK689, respectively), were isolated. Sixteen random hlyA mutations were identified on the basis of a screen for loss of immunoreactivity to the hemolysin-neutralizing D12 monoclonal antibody that reacts to only HlyC-activated HlyA. These substitutions occurred at the region from HlyAE684 to HlyAY696. A recombinant glutathione S-transferase-hemolysin gene fusion encoding glutathione S-transferase-HlyAS608-T725 residues reacts with monoclonal antibody when HlyC is coexpressed with the fusion protein. Therefore, at most only 12% of the total HlyA primary sequence is needed for HlyC-facilitated acylation at the HlyAK689 position, and this modification can occur in the absence of the proximal HlyAK563 acylation site. The cytolytic activities of these HlyA mutants against sheep erythrocytes and bovine and human lymphocyte cell lines (BL-3 and Raji cells, respectively) were analyzed. HlyAK563 and HlyAK689 substitutions displayed various degrees of loss of cytotoxicity that depended on the particular amino acid replacement. An HlyAK563C variant retained greater than 59 and 21% of its BL-3-lytic and erythrolytic activities, respectively, but was nearly inactive against Raji cells. An HlyA mutant with a K-to-E substitution at amino acid 689 (HlyAK689E) was essentially inactive against all three cell types, whereas an HlyAK689R substitution had a pattern of activity similar to that of the HlyAK563C mutant. Preceding the two in vitro acylated HlyA lysines are glycines that appear to be the only amino acids conserved in alignments of these regions among the RTX toxins. Remarkably, considering the retention of cytotoxic activity by some HlYAK689 mutants, each of three different substitutions at the HlyAG688 position was relatively inactive against all three cell types tested. This suggests that HlyAG688 plays a significant structural role in cytotoxic activity apart from its possible participation in an HlyC activation process which presumably requires recognition of pro-HlyA structures. The related RTX toxin, the Pasteurella haemolytica leukotoxin structural protein (LktA), can be activated in an E. coli recombinant background by HlyC. In amino acid sequence alignments, LktAK554 is equivalent to the HlyAK563 position but it has an asparagine (LktAN684) at the homologous HlyAK689 site. An LktAN684K substitution possesses wild-type leukotoxin activity against BL-3 cells and does not acquire hemolytic or Raji cell cytotoxic activity. Surprisingly, both LktAK554C and LktAK554T substitutions retain considerable BL-3 cytotoxicity (45 and 49%, respectively), indicating that there may be additional lysines within LktA that the HlyC activation mechanism is capable of acylating. Based on these results and a comparison of amino acid sequence alignments of 12 RTX toxins, a putative consensus structure of the RTX residues necessary for HlyC activation is hypothesized.

Full Text

The Full Text of this article is available as a PDF (291.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry E. M., Weiss A. A., Ehrmann I. E., Gray M. C., Hewlett E. L., Goodwin M. S. Bordetella pertussis adenylate cyclase toxin and hemolytic activities require a second gene, cyaC, for activation. J Bacteriol. 1991 Jan;173(2):720–726. doi: 10.1128/jb.173.2.720-726.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bauer M. E., Welch R. A. Characterization of an RTX toxin from enterohemorrhagic Escherichia coli O157:H7. Infect Immun. 1996 Jan;64(1):167–175. doi: 10.1128/iai.64.1.167-175.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chou P. Y., Fasman G. D. Prediction of protein conformation. Biochemistry. 1974 Jan 15;13(2):222–245. doi: 10.1021/bi00699a002. [DOI] [PubMed] [Google Scholar]
  4. Czuprynski C. J., Welch R. A. Biological effects of RTX toxins: the possible role of lipopolysaccharide. Trends Microbiol. 1995 Dec;3(12):480–483. doi: 10.1016/s0966-842x(00)89016-2. [DOI] [PubMed] [Google Scholar]
  5. Emini E. A., Hughes J. V., Perlow D. S., Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol. 1985 Sep;55(3):836–839. doi: 10.1128/jvi.55.3.836-839.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Felmlee T., Pellett S., Welch R. A. Nucleotide sequence of an Escherichia coli chromosomal hemolysin. J Bacteriol. 1985 Jul;163(1):94–105. doi: 10.1128/jb.163.1.94-105.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Forestier C., Welch R. A. Identification of RTX toxin target cell specificity domains by use of hybrid genes. Infect Immun. 1991 Nov;59(11):4212–4220. doi: 10.1128/iai.59.11.4212-4220.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Garnier J., Osguthorpe D. J., Robson B. Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol. 1978 Mar 25;120(1):97–120. doi: 10.1016/0022-2836(78)90297-8. [DOI] [PubMed] [Google Scholar]
  9. Hackett M., Guo L., Shabanowitz J., Hunt D. F., Hewlett E. L. Internal lysine palmitoylation in adenylate cyclase toxin from Bordetella pertussis. Science. 1994 Oct 21;266(5184):433–435. doi: 10.1126/science.7939682. [DOI] [PubMed] [Google Scholar]
  10. Hackett M., Walker C. B., Guo L., Gray M. C., Van Cuyk S., Ullmann A., Shabanowitz J., Hunt D. F., Hewlett E. L., Sebo P. Hemolytic, but not cell-invasive activity, of adenylate cyclase toxin is selectively affected by differential fatty-acylation in Escherichia coli. J Biol Chem. 1995 Sep 1;270(35):20250–20253. doi: 10.1074/jbc.270.35.20250. [DOI] [PubMed] [Google Scholar]
  11. Kunkel T. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A. 1985 Jan;82(2):488–492. doi: 10.1073/pnas.82.2.488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lo R. Y., Strathdee C. A., Shewen P. E. Nucleotide sequence of the leukotoxin genes of Pasteurella haemolytica A1. Infect Immun. 1987 Sep;55(9):1987–1996. doi: 10.1128/iai.55.9.1987-1996.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Low B. Formation of merodiploids in matings with a class of Rec- recipient strains of Escherichia coli K12. Proc Natl Acad Sci U S A. 1968 May;60(1):160–167. doi: 10.1073/pnas.60.1.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ludwig A., Benz R., Goebel W. Oligomerization of Escherichia coli haemolysin (HlyA) is involved in pore formation. Mol Gen Genet. 1993 Oct;241(1-2):89–96. doi: 10.1007/BF00280205. [DOI] [PubMed] [Google Scholar]
  15. Messing J. New M13 vectors for cloning. Methods Enzymol. 1983;101:20–78. doi: 10.1016/0076-6879(83)01005-8. [DOI] [PubMed] [Google Scholar]
  16. Moayeri M., Welch R. A. Effects of temperature, time, and toxin concentration on lesion formation by the Escherichia coli hemolysin. Infect Immun. 1994 Oct;62(10):4124–4134. doi: 10.1128/iai.62.10.4124-4134.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pellett S., Boehm D. F., Snyder I. S., Rowe G., Welch R. A. Characterization of monoclonal antibodies against the Escherichia coli hemolysin. Infect Immun. 1990 Mar;58(3):822–827. doi: 10.1128/iai.58.3.822-827.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Robson B., Suzuki E. Conformational properties of amino acid residues in globular proteins. J Mol Biol. 1976 Nov 5;107(3):327–356. doi: 10.1016/s0022-2836(76)80008-3. [DOI] [PubMed] [Google Scholar]
  19. Rowe G. E., Pellett S., Welch R. A. Analysis of toxinogenic functions associated with the RTX repeat region and monoclonal antibody D12 epitope of Escherichia coli hemolysin. Infect Immun. 1994 Feb;62(2):579–588. doi: 10.1128/iai.62.2.579-588.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Smith D. B., Johnson K. S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988 Jul 15;67(1):31–40. doi: 10.1016/0378-1119(88)90005-4. [DOI] [PubMed] [Google Scholar]
  21. Stanley P., Packman L. C., Koronakis V., Hughes C. Fatty acylation of two internal lysine residues required for the toxic activity of Escherichia coli hemolysin. Science. 1994 Dec 23;266(5193):1992–1996. doi: 10.1126/science.7801126. [DOI] [PubMed] [Google Scholar]
  22. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Welch R. A., Bauer M. E., Kent A. D., Leeds J. A., Moayeri M., Regassa L. B., Swenson D. L. Battling against host phagocytes: the wherefore of the RTX family of toxins? Infect Agents Dis. 1995 Dec;4(4):254–272. [PubMed] [Google Scholar]
  24. Welch R. A., Hull R., Falkow S. Molecular cloning and physical characterization of a chromosomal hemolysin from Escherichia coli. Infect Immun. 1983 Oct;42(1):178–186. doi: 10.1128/iai.42.1.178-186.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Welch R. A., Pellett S. Transcriptional organization of the Escherichia coli hemolysin genes. J Bacteriol. 1988 Apr;170(4):1622–1630. doi: 10.1128/jb.170.4.1622-1630.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES